LDS/Medical Tests/CD8 Lymphocyte Count

CD8 Lymphocyte Count

Cytotoxic T-cells, also known as CD8 cells and "killer" T cells, are a type of white blood cell called lymphocytes and are part of the cell-mediated immunity immune response. There are different T-cells that play a part in our immunity and are distinguished by certain receptors (antigens) present on their outer membrane. CD8 cells will identify and kill cells that are infected with a virus, other intracellular organism or are abnormal such as cancer cells. When the virus enters the cell and begins to replicate and produce new viruses, they leave certain viral fragments behind.  Parts of the virus are presented to the T cell receptor by a Major Histocompatibility Complex protein. This process requires the CD8 molecule on the T cell to bind to the MHC molecule so that the antigen is stabilized long enough for T cell activation to occur.  The CD8 cells specific for the antigens on these fragments will destroy the cell before it can create more virus. Cytotoxic T cells are responsible for most of the damage to the liver when Hepatitis B is present, but it successfully destroys the cells that are infected. When a patient is infected with HIV, the HIV virus preferrentially infects CD4+ T cells and destroys them, while leaving CD8+ T cells unharmed.  This reduces the ratio of CD4 to CD8 T cells. Healthy patients normally have a CD4:CD8 ratio of >1.0. In people with HIV, the ratio decreases due to the destruction of CD4 cells by the HIV virus.  CD 4 T cells are very important in the immune system's ability to fight infection.  When their numbers decrease to a critical level, patients can not fight certain types of infections and symptoms of AIDS will appear. This makes the CD4 and CD8 counts and their ratio very important in monitoring the status of the immune system and starting or changing anti-viral therapy. Monitoring CD8 T cells alone is an indicator of immune system status.  It can be used to monitor for overimmunosuppression in patients following hematopoietic stem cell transplant or who are are maintenance immunosuppressive therapy following solid organ transplant.  CD8 will increase in certain cancers, disorders, and infections other than HIV such as measles, burns, or infectious mononucleosis.

  • In diagnosis of AIDS due to human immunodeficiency virus infection
  • Monitoring patients with human immunodeficiency virus infection
  • Therapy treatment decisions in patients with human immunodeficiency virus
  • As an aid in evaluation of some other immunodeficiencies other than AIDS
  • Monitoring hematopoietic stem cell transplant patients on immunosuppressive therapy
  • Monitoring solid organ transplant patients on immunosuppressive therapy
  • Monitoring certain cancer patients on chemotherapy

Increased in:

  • HIV infection
  • Some other viral infections
  • Cancers
  • Some autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), and chronic autoimmune hepatitis
  • Type I diabetes mellitus
  • Primary biliary cirrhosis
  • Atopic dermatitis
  • Psoriasis

Decreased in:

  • Myelodysplastic syndromes
  • Acute lymphoblastic leukemia in remission
  • Recovery from bone marrow transplantation
  • Some idiopathic lymphocytopenias

CD8: 80 – 1400 cells/mcL (8 - 41%)

 

 

Flow cytometry

Whole blood collected in green top (heparin) or lavender top (EDTA) tube. 

Specimens must be kept at room temperature and analyzed within 72 hours of collection in EDTA or within 48 hours in heparin.

Some medications may affect immunophenotyping results and should be listed on the patient test request form.

Complete blood count (CBC) with manual diff, CD4 count, CD4/CD8 cell count and ratio, CD3, HIV antibody screen, HIV western blot, HIV viral load, HIV genotypic resistance testing, HIV phenotypic resistance testing.
1-2 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Proc Natl Acad Sci USA. 2007 Apr 17;104(16):6776-81 [PMID: 17428922]
  • AIDS. 1999 Dec 3;13(17):2365-76. [PMID: 10597778]
  • JAMA. 2006;296:827. [PMID: 16905788]
  • Nature. 2001 Apr 19;410(6831):980-7. [PMID: 11309628]
  • Iannacone M, Sitia G, and Guidotti LG. Pathogenetic and antiviral immune responses against hepatitis B virus. Future Virology. 2006; 1: 189–96. doi:10.2217/17460794.1.2.189.